JP2017538672A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538672A5 JP2017538672A5 JP2017522532A JP2017522532A JP2017538672A5 JP 2017538672 A5 JP2017538672 A5 JP 2017538672A5 JP 2017522532 A JP2017522532 A JP 2017522532A JP 2017522532 A JP2017522532 A JP 2017522532A JP 2017538672 A5 JP2017538672 A5 JP 2017538672A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cmv
- amino acid
- acid sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 239000000427 antigen Substances 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 229920001184 polypeptide Polymers 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 11
- 241001465754 Metazoa Species 0.000 claims 10
- 235000001014 amino acid Nutrition 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 9
- 101710132601 Capsid protein Proteins 0.000 claims 4
- 101710094648 Coat protein Proteins 0.000 claims 4
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims 4
- 101710125418 Major capsid protein Proteins 0.000 claims 4
- 101710141454 Nucleoprotein Proteins 0.000 claims 4
- 101710083689 Probable capsid protein Proteins 0.000 claims 4
- 210000004897 n-terminal region Anatomy 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 239000013566 allergen Substances 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 230000007815 allergy Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 claims 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- 241000223960 Plasmodium falciparum Species 0.000 claims 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 2
- 102000003802 alpha-Synuclein Human genes 0.000 claims 2
- 108090000185 alpha-Synuclein Proteins 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 241000282465 Canis Species 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 102100023688 Eotaxin Human genes 0.000 claims 1
- 101710139422 Eotaxin Proteins 0.000 claims 1
- 241000282324 Felis Species 0.000 claims 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims 1
- 101900330356 Influenza A virus Matrix protein 2 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000009053 Neurodermatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims 1
- 108010055044 Tetanus Toxin Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 229960003604 testosterone Drugs 0.000 claims 1
- 229940118376 tetanus toxin Drugs 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14189897.3 | 2014-10-22 | ||
| EP14189897 | 2014-10-22 | ||
| EP15184192 | 2015-09-08 | ||
| EP15184192.1 | 2015-09-08 | ||
| PCT/EP2015/074269 WO2016062720A1 (en) | 2014-10-22 | 2015-10-20 | Modified virus-like particles of cmv |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017538672A JP2017538672A (ja) | 2017-12-28 |
| JP2017538672A5 true JP2017538672A5 (enExample) | 2018-11-22 |
| JP6942313B2 JP6942313B2 (ja) | 2021-09-29 |
Family
ID=54337283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017522532A Active JP6942313B2 (ja) | 2014-10-22 | 2015-10-20 | Ｃｍｖ由来改変ウイルス様粒子 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10532107B2 (enExample) |
| EP (1) | EP3209326A1 (enExample) |
| JP (1) | JP6942313B2 (enExample) |
| KR (2) | KR102775741B1 (enExample) |
| CN (2) | CN108064276B (enExample) |
| AU (1) | AU2015335027B2 (enExample) |
| CA (1) | CA2963709A1 (enExample) |
| CL (1) | CL2017000987A1 (enExample) |
| CO (1) | CO2017004119A2 (enExample) |
| IL (1) | IL251532B (enExample) |
| MA (1) | MA40824A (enExample) |
| MX (1) | MX387985B (enExample) |
| MY (1) | MY187462A (enExample) |
| NZ (1) | NZ731205A (enExample) |
| PE (1) | PE20171133A1 (enExample) |
| PH (1) | PH12017500727A1 (enExample) |
| RU (1) | RU2706970C2 (enExample) |
| SG (2) | SG11201703083QA (enExample) |
| TN (1) | TN2017000133A1 (enExample) |
| WO (1) | WO2016062720A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40824A (fr) * | 2014-10-22 | 2017-08-29 | Saiba Gmbh | Particules de cmv de type virus modifié |
| WO2017179025A1 (en) | 2016-04-15 | 2017-10-19 | Alk-Abelló A/S | Epitope polypeptides of ragweed pollen allergens |
| MX394254B (es) * | 2016-04-27 | 2025-03-24 | Benchmark Animal Health Ltd | Composiciones para el tratamiento de dermatitis atópica canina y sus usos. |
| WO2017186808A1 (en) * | 2016-04-27 | 2017-11-02 | Allergy Therapeutics (Uk) Limited | Treatment of peanut allergy |
| WO2018162577A1 (en) | 2017-03-07 | 2018-09-13 | Universität Zürich | Treatment of pruritus in horses |
| CA3085318A1 (en) * | 2017-12-11 | 2019-06-20 | Ubi Ip Holdings | Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis |
| JP7497293B2 (ja) * | 2018-03-16 | 2024-06-10 | ゾエティス・サービシーズ・エルエルシー | インターロイキン－３１に対するペプチドワクチン |
| US10828351B2 (en) | 2018-04-10 | 2020-11-10 | Ac Immune Sa | Anti-abeta therapeutic vaccines |
| CA3097954A1 (en) | 2018-05-28 | 2019-12-05 | Evax Ag | Treatment of urticaria |
| PH12021550898A1 (en) * | 2018-12-20 | 2022-05-02 | Saiba AG | Virus-like particles of cmv modified by fusion |
| AU2019418627A1 (en) * | 2018-12-31 | 2021-07-29 | United Neuroscience Limited | Peptide immunogens targeting Calcitonin Gene-Related Peptide (CGRP) and formulations thereof for prevention and treatment of migraine |
| WO2021083766A1 (en) | 2019-10-29 | 2021-05-06 | Evax Ag | Treatment of pruritus in horses |
| US20230038487A1 (en) * | 2019-11-25 | 2023-02-09 | The Regents Of The University Of California | Modified viral therapeutics and uses thereof |
| WO2021260131A1 (en) | 2020-06-25 | 2021-12-30 | Saiba AG | Virus-like particles of cmv modified by fusion |
| TW202233584A (zh) * | 2020-11-11 | 2022-09-01 | 歐洲分子生物學實驗室 | 用於基因治療之經修飾病毒顆粒 |
| AU2021383841A1 (en) * | 2020-11-23 | 2023-06-22 | Scout Bio, Inc. | Antigen-binding molecules and uses thereof |
| CN117534736A (zh) * | 2020-12-15 | 2024-02-09 | 深圳赫兹生命科学技术有限公司 | 一种用于生产vlp重组疫苗的cmv病毒样颗粒及其制备方法 |
| JP2025504361A (ja) | 2022-01-19 | 2025-02-12 | ウニベルズィテート ベルン | ウイルス様粒子と微結晶性チロシンとの組成物 |
| CN114437211B (zh) * | 2022-01-26 | 2024-03-12 | 南京麦西崴克生物科技有限公司 | 基于猫过敏原Fel d1的卵黄抗体的制备方法 |
| EP4486387A1 (en) | 2022-02-28 | 2025-01-08 | Tridem Bioscience GmbH & Co KG | A conjugate consisting of or comprising at least a ss-glucan or a mannan |
| AU2023225283A1 (en) | 2022-02-28 | 2024-08-22 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN. |
| WO2024047090A2 (en) | 2022-08-30 | 2024-03-07 | Saiba Animal Health Ag | Modified virus-like particles of cmv |
| CN118684781A (zh) * | 2023-03-21 | 2024-09-24 | 深圳赫兹生命科学技术有限公司 | GnRH-VLP重组去势疫苗及其制备方法 |
| GB202400747D0 (en) * | 2024-01-19 | 2024-03-06 | Univ Dundee | IL31-VLP and medical uses thereof |
| WO2025186188A1 (en) | 2024-03-04 | 2025-09-12 | Boehringer Ingelheim Vetmedica Gmbh | Active vaccination for the treatment of ngf-related disorders |
| US20250281585A1 (en) | 2024-03-06 | 2025-09-11 | Elanco Us Inc. | Veterinary compositions of modified virus-like particles of cmv and il-1 beta mutein antigens |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6419931B1 (en) * | 1991-08-26 | 2002-07-16 | Epimmune Inc. | Compositions and methods for eliciting CTL immunity |
| AU4826799A (en) * | 1998-06-20 | 2000-01-10 | United Biomedical Inc. | Synthetic somatostatin immunogen for growth promotion in farm animals |
| AU2001252458A1 (en) * | 2000-05-05 | 2001-11-20 | Martin Bachmann | Molecular antigen arrays and vaccines |
| AU7658101A (en) * | 2000-07-28 | 2002-02-13 | Cytos Biotechnology Ag | Compositions for inducing self-specific anti-ige antibodies and uses thereof |
| JP4533626B2 (ja) * | 2001-11-07 | 2010-09-01 | サイトス バイオテクノロジー アーゲー | アレルギー性好酸球性疾患を治療するための抗原アレイ |
| PL369863A1 (en) | 2001-11-07 | 2005-05-02 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
| US20040033585A1 (en) | 2002-06-07 | 2004-02-19 | Mccormick Alison A. | Flexible vaccine assembly and vaccine delivery platform |
| GB0228715D0 (en) * | 2002-12-09 | 2003-01-15 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2005091753A2 (en) * | 2004-03-25 | 2005-10-06 | Large Scale Biology Corporation | Flexible vaccine assembly and vaccine delivery platform |
| BRPI0516953A (pt) | 2004-09-21 | 2008-09-30 | Cytos Biotechnology Ag | partìculas do tipo vìrus compreendendo uma proteìna de fusão da proteìna de revestimento de ap205 e um polipeptìdeo antigênico |
| EP1856150A2 (en) * | 2005-02-14 | 2007-11-21 | ZymoGenetics, Inc. | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
| KR20070112225A (ko) * | 2005-03-18 | 2007-11-22 | 사이토스 바이오테크놀로지 아게 | 고양이 알레르겐 컨쥬게이트 및 그의 용도 |
| EP1973608A1 (en) * | 2005-12-14 | 2008-10-01 | Cytos Biotechnology AG | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
| US20110293700A1 (en) * | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| HUP1100470A2 (en) * | 2011-08-30 | 2013-03-28 | Mezoegazdasagi Biotechnologiai Kutatokoezpont | Nanoparticle-based veterinary vaccine |
| CN102943087A (zh) * | 2012-11-26 | 2013-02-27 | 中国农业科学院上海兽医研究所 | 兔出血症病毒新型亚单位疫苗及其制备方法 |
| JP6190898B2 (ja) | 2013-10-28 | 2017-08-30 | 株式会社日立製作所 | サーバに接続されるシステム及び仮想マシンが動作しているサーバに接続されたシステムによる方法 |
| MA40824A (fr) * | 2014-10-22 | 2017-08-29 | Saiba Gmbh | Particules de cmv de type virus modifié |
| KR102812106B1 (ko) * | 2015-09-08 | 2025-05-22 | 유니베르시태트 취리히 | 고양이 알레르기 억제 조성물 |
| BR112018003967A2 (en) * | 2015-09-08 | 2018-09-25 | Universität Zürich | Insect bite hypersensitivity treatment |
-
2015
- 2015-10-19 MA MA040824A patent/MA40824A/fr unknown
- 2015-10-20 SG SG11201703083QA patent/SG11201703083QA/en unknown
- 2015-10-20 RU RU2017111266A patent/RU2706970C2/ru active
- 2015-10-20 KR KR1020177013820A patent/KR102775741B1/ko active Active
- 2015-10-20 US US15/520,676 patent/US10532107B2/en active Active
- 2015-10-20 CA CA2963709A patent/CA2963709A1/en active Pending
- 2015-10-20 TN TN2017000133A patent/TN2017000133A1/en unknown
- 2015-10-20 MY MYPI2017701368A patent/MY187462A/en unknown
- 2015-10-20 PE PE2017000737A patent/PE20171133A1/es unknown
- 2015-10-20 MX MX2017005242A patent/MX387985B/es unknown
- 2015-10-20 EP EP15781949.1A patent/EP3209326A1/en active Pending
- 2015-10-20 CN CN201580064884.XA patent/CN108064276B/zh active Active
- 2015-10-20 NZ NZ731205A patent/NZ731205A/en unknown
- 2015-10-20 WO PCT/EP2015/074269 patent/WO2016062720A1/en not_active Ceased
- 2015-10-20 SG SG10201903538YA patent/SG10201903538YA/en unknown
- 2015-10-20 AU AU2015335027A patent/AU2015335027B2/en active Active
- 2015-10-20 JP JP2017522532A patent/JP6942313B2/ja active Active
- 2015-10-20 KR KR1020257006196A patent/KR20250034187A/ko active Pending
- 2015-10-20 CN CN202210351341.8A patent/CN114685626B/zh active Active
-
2017
- 2017-04-03 IL IL251532A patent/IL251532B/en active IP Right Grant
- 2017-04-20 CL CL2017000987A patent/CL2017000987A1/es unknown
- 2017-04-20 PH PH12017500727A patent/PH12017500727A1/en unknown
- 2017-04-27 CO CONC2017/0004119A patent/CO2017004119A2/es unknown
-
2019
- 2019-11-26 US US16/696,161 patent/US11324836B2/en active Active
-
2022
- 2022-04-06 US US17/714,307 patent/US20220305131A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538672A5 (enExample) | ||
| RU2017111266A (ru) | Модифицированные вирусоподобные частицы вируса мозаики огурца | |
| Balke et al. | Recent advances in the use of plant virus-like particles as vaccines | |
| RU2486206C2 (ru) | Гипоаллергенный слитый белок, молекула нуклеиновой кислоты, кодирующая его, вектор экспрессии, клетка-хозяин, вакцинная композиция и его применение | |
| JP2014530010A5 (enExample) | ||
| Deng et al. | Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge | |
| JP2015501840A5 (enExample) | ||
| HRP20171213T1 (hr) | Glikoproteinske čestice nalik virusu (vlp) bjesnoće | |
| JP2010516290A5 (enExample) | ||
| Shim et al. | Sublingual delivery of vaccines for the induction of mucosal immunity | |
| JP2011250797A5 (enExample) | ||
| JP2019506175A5 (enExample) | ||
| EA202090738A1 (ru) | Способ безопасного индуцирования иммунитета против rsv | |
| Chai et al. | DNA vaccination induced protective immunity against SARS CoV-2 infection in hamsterss | |
| JP2024504566A (ja) | 核酸ワクチン | |
| TW202202169A (zh) | 預防嚴重急性呼吸症候群冠狀病毒第二型（ｓａｒｓ－ｃｏｖ－２）感染的生物可降解奈米複合物疫苗及方法 | |
| JP2016511747A5 (enExample) | ||
| JP2010506926A5 (enExample) | ||
| Nagpal et al. | Current clinical status of new COVID-19 vaccines and immunotherapy | |
| Mansoor et al. | Intranasal delivery of nanoparticles encapsulating BPI3V proteins induces an early humoral immune response in mice | |
| JP2015529677A5 (enExample) | ||
| Nie et al. | Self-adjuvant multiepitope nanovaccine based on ferritin induced long-lasting and effective mucosal immunity against H3N2 and H1N1 viruses in mice | |
| Ramirez et al. | Co‐Delivery of Multiple Toll‐Like Receptor Agonists and Avian Influenza Hemagglutinin on Protein Nanoparticles Enhances Vaccine Immunogenicity and Efficacy | |
| Ding et al. | A Universal Influenza Nanovaccine for “Mixing Vessel” Hosts Confers Potential Ability to Block Cross‐Species Transmission | |
| Zhang et al. | Multi-COBRA hemagglutinin formulated with cGAMP microparticles elicits protective immune responses against influenza viruses |